Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) reiterates its commitment in supporting a clinical trial to prevent symptomatic SARS-CoV-2 infections by donating Chloroquine Phosphate (CQ) Tablets through its marketing partner in the United States, Rising Pharmaceuticals, to a study conducted by Columbia University, New York.
After NATCO's recent donation to a global clinical trial conducted by the CROWN (COVID-19 Research Outcomes Worldwide Network) Collaborative at the Washington University School of Medicine in St. Louis it has now committed to support the Phase 2 of a clinical trial at Columbia University. The trial aims to determine the effectiveness of CQ in preventing COVID-19 infection in healthcare workers with moderate to high risk of exposure to the virus.
Researchers at Columbia University are conducting this critical study to assess CQ as prophylaxis against COVID-19 in healthcare workers. The Phase 2 trial will enroll 350 volunteers who work in direct patient care roles at Columbia University Irving Medical Center and who have contact with patients who may have COVID-19 infection.
NATCO has been supplying CQ Tablets, a USFDA approved drug, through its marketing partner to the United States since 2011. Columbia University, a private Ivy League research university in New York City established in 1754 is renowned across the world for its expertise in conducting well designed clinical trials and NATCO is glad to work with them on this path breaking trial.
Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.594.95 as compared to the previous close of Rs. 593.55. The total number of shares traded during the day was 409951 in over 997 trades.
The stock hit an intraday high of Rs. 603.85 and intraday low of 590. The net turnover during the day was Rs. 241932311.